SOURCE: Eugene Science, Inc.

September 18, 2007 08:30 ET

Eugene Science Retains Leading U.S. - China Marketing Firm; TCG to Promote Company's CholZero™ in China B2B Campaign

LOS ANGELES, CA--(Marketwire - September 18, 2007) - Eugene Science (OTCBB: EUSI), developer and marketer of advanced health supplements and nutraceutical products, today announced it has retained Transworld Consulting Group, Inc. (TCG) for promotion of the Company's cholesterol reducing plant sterols and CholZero™ product line throughout China.

With offices in Los Angeles, Shanghai and Beijing, TCG is a highly regarded consulting firm focused on U.S. - China transnational marketing, finance and M&A. TCG founder and CEO Jack Chen has 14 years experience assisting U.S. and Chinese companies and government ministries to successfully enter and gain share in both markets. TCG has assisted companies including Ford Motor Company, Aegon, Best Western Hotels, Panda Restaurant Group and Composite Technologies and others with their China marketing strategy.

For Eugene Science, TCG has developed and is implementing a business to business marketing campaign to promote the Company's cholesterol reducing plant sterols and CholZero™ product line to food manufacturing and distribution companies throughout China, Hong Kong and Taiwan.

China offers a huge potential market of 1.32 billion consumers (with rapidly growing meat and dairy consumption and an awareness of cholesterol as an important health issue); 72 percent of the Chinese population is between 15 and 64 years of age.

Jack Chen, TCG president, said, "The health benefits of plant sterols have long been recognized in China. Plant sterols are derived from soy beans, an integral part of the Asian diet. Incorporating Eugene Science's CholZero™ nano-technology enhanced functional food additive into the Chinese food and beverage market is a logical and timely opportunity for which we have already identified strong interest."

The Eugene Science CholZero™ product line is currently being sold throughout Japan, Korea, Malaysia and elsewhere and includes pre-cooked rice, cooking oil, beverages, capsules, tablets, seaweed and ice cream. The CholZero™ ingredient is produced with a proprietary, patented nano-technology process to render it water soluble with bio-absorbency and efficacy properties far superior to other products in the market.

"Global economists agree China is to become the world's largest, fast growing consumption marketplace," said Seung Kwon Noh, Chief Executive Officer, Eugene Science. "Following on the strong initial reception of CholZero in other parts of Asia, China is the right market at the right time. We are delighted to have TCG aggressively representing our interests in the region."

For additional information on TCG, please visit: http://www.consulting-tcg.com

About Eugene Science, Inc.

Based in Bucheon, Kyunggi-Do, Korea, Eugene Science is a global biotechnology company tackling ailments such as heart disease, obesity and diabetes through innovation in the nutraceutical field. Its first commercial heart disease product, CZ™, is a patented, nanoscience-based, water-soluble functional food ingredient containing natural plant sterols that help maintain healthy cholesterol levels by inhibiting its absorption. CZ™ is available in capsule form, or as a food or beverage additive. These plant sterols are approved by the U.S. FDA for health claims related to cholesterol lowering efficacy. Please visit www.eugene21.com.

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition, from time to time, Eugene Science, or its representatives, have made or may make forward-looking statements, orally or in writing. The words "estimate," "project," "potential," "intended," "expect," "anticipate," "believe" and similar expressions or words are intended to identify forward-looking statements. Such forward-looking statements may be included in, but are not limited to, various filings made by Eugene Science with the United States Securities and Exchange Commission (available at www.sec.gov), press releases or oral statements made with the approval of an authorized executive officer of Eugene Science. Actual results could differ materially from those projected or suggested in any forward-looking statements as a result of a wide variety of factors and conditions. Reference is hereby made to Eugene Science's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006 for information regarding those factors and conditions. Among the important factors that could cause actual results to differ materially from management's projections, estimates and expectations include, but are not limited to: changing economic influences in the nutraceutical industry; dependence on key personnel; actions of third parties; the market for nutraceutical products containing Eugene Science's CZ™ ingredient, and availability of adequate financing. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only as of the date of this press release. Eugene Science undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Contact Information

  • Investor Relations:
    Mirador Consulting, Inc.
    Rich Miller
    (561) 989-3600